Literature DB >> 34053133

Recent advances in gene therapy for atrial fibrillation.

Shin Yoo1, Gail Elizabeth Geist1, Anna Pfenniger1, Markus Rottmann1, Rishi Arora1.   

Abstract

Atrial fibrillation (AF) is the most common heart rhythm disorder in adults and a major cause of stroke. Unfortunately, current treatments for AF are suboptimal as they are not targeting the molecular mechanisms underlying AF. In this regard, gene therapy is emerging as a promising approach for mechanism-based treatment of AF. In this review, we summarize recent advances and challenges in gene therapy for this important cardiovascular disease.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  atrial fibrillation; gene therapy

Mesh:

Year:  2021        PMID: 34053133      PMCID: PMC9281901          DOI: 10.1111/jce.15116

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873            Impact factor:   2.942


  120 in total

1.  ADENOVIRUS-ASSOCIATED DEFECTIVE VIRUS PARTICLES.

Authors:  R W ATCHISON; B C CASTO; W M HAMMON
Journal:  Science       Date:  1965-08-13       Impact factor: 47.728

2.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors:  Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

3.  Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions.

Authors:  Itay Perlstein; Denise Y Burton; Kenneth Ryan; Suzanne Defelice; Erin Simmers; Barry Campbell; Jeanne M Connolly; Amnon Hoffman; Robert J Levy
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

4.  Long-lasting in vivo gene silencing by electrotransfer of shRNA expressing plasmid.

Authors:  Jean-Michel Escoffre; Arnaud Debin; Jean-Paul Reynes; Daniel Drocourt; Gérard Tiraby; Laëtitia Hellaudais; Justin Teissie; Muriel Golzio
Journal:  Technol Cancer Res Treat       Date:  2008-04

5.  Prolonged in vivo gene silencing by electroporation-mediated plasmid delivery of small interfering RNA.

Authors:  Daniël Eefting; Jos M Grimbergen; Margreet R de Vries; Vincent van Weel; Eric L Kaijzel; Ivo Que; Randall T Moon; Clemens W Löwik; J Hajo van Bockel; Paul H A Quax
Journal:  Hum Gene Ther       Date:  2007-09       Impact factor: 5.695

6.  Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.

Authors:  D Li; S Fareh; T K Leung; S Nattel
Journal:  Circulation       Date:  1999-07-06       Impact factor: 29.690

Review 7.  Cardiac ionic currents and acute ischemia: from channels to arrhythmias.

Authors:  E Carmeliet
Journal:  Physiol Rev       Date:  1999-07       Impact factor: 37.312

8.  Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction.

Authors:  Yoav Hadas; Adam S Vincek; Elias Youssef; Magdalena M Żak; Elena Chepurko; Nishat Sultana; Mohammad Tofael Kabir Sharkar; Ningning Guo; Rinat Komargodski; Ann Anu Kurian; Keerat Kaur; Ajit Magadum; Anthony Fargnoli; Michael G Katz; Nadia Hossain; Ephraim Kenigsberg; Nicole C Dubois; Eric Schadt; Roger Hajjar; Efrat Eliyahu; Lior Zangi
Journal:  Circulation       Date:  2020-01-29       Impact factor: 29.690

9.  Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study.

Authors:  Kerstin Trappe; Dierk Thomas; Olympia Bikou; Kamilla Kelemen; Patrick Lugenbiel; Frederik Voss; Rüdiger Becker; Hugo A Katus; Alexander Bauer
Journal:  Eur Heart J       Date:  2011-07-23       Impact factor: 29.983

Review 10.  Gene Therapy Leaves a Vicious Cycle.

Authors:  Reena Goswami; Gayatri Subramanian; Liliya Silayeva; Isabelle Newkirk; Deborah Doctor; Karan Chawla; Saurabh Chattopadhyay; Dhyan Chandra; Nageswararao Chilukuri; Venkaiah Betapudi
Journal:  Front Oncol       Date:  2019-04-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.